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Bone marrow (BM) stromal cells (also termed mesenchymal
stem cells; MSC) have been extensively studied and shown to
control differentiation of hematopoietic stem cells (HSCs) in
part through secreted growth factors. In addition, MSCs
support the growth of tumor cells both in vitro and in vivo.
As MSCs are being evaluated in a number of clinical trials for
regenerative medicine approaches, it is critical to understand
the role of stromal cells in different tissues. Stromal cells
were isolated from various human tissues including adipose
(Ad), cardiac (Car) and liver (Liv) tissues as well as bone
marrow (BM) and had an identical appearance in culture. We
have compared the stromal cells from these tissues and
demonstrate that although they have similar morphology
and surface marker expression (CD105+/CD90+/CD73+ and
CD45-/CD34-) they have differential biological properties.
BM MSCs have been shown previously to support both
normal hematopoietic cells and tumor cells.
To test the functional properties of the stromal cell lines we
co-cultured stromal cells with either cord blood (CB) cells or
tumor cells (K562). As we have previously reported, co-cul-
ture of CB on BM-MSCs resulted in expansion of hemato-
poietic cells. Similarly, Ad stromal cells supported expansion
of hematopoietic cells, however, Liv and Car stromal cells
failed to expand the CB cells. The effect of the Car stromawas
through a cytostatic mechanism as removal of the CB cells
from the stromal cells after 7 days of co-culture resulted
in hematopoietic cell expansion and detection of colony
forming cells by methycellulose assay. We also tested the
potential of the stromal cells to support tumor cell growth by
co-culturing K562 cells with the stromal cells. Ad and Liv
stroma supported growth of the K562 cells similar to BM
MSCs, while Car stromal cells inhibited K562 cell growth
with few viable cells after 7 days of culture.
These data suggest that the function of stromal cells from
different tissue is variable. In particular, tumor development
in cardiac tissue is a rare event and our data suggest that Car
stromal cells may play a key role in inhibiting proliferation of
tumor cells. Further we propose that non homologous use of
stromal cells in clinical applications may have deleterious
effects, for example the use of BM-MSCs to repair ischemic
tissue in the heart may lead to a tumor supportive environ-
ment in cardiac tissue.
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plantation incorporates chemotherapy and/or radiotherapy
to eradicate malignant disease, eliminate immunologic
barriers to allogeneic cell engraftment, and to ‘make space’
for donor HSC within the HSC niche. The sequelae of such
treatments can be substantial, including direct organ
toxicity. Selective targeting of HSC with monoclonal anti-
bodies presents an alternative approach to induce stem cell
depletion with fewer off target effects. Previous studies in a
congenic mouse transplant model established that anti-
body-mediated blockade of c-Kit, the receptor for stem cell
factor, given in combination with low dose irradiation
(LD-IR) efﬁciently depletes HSC and substantially enhances
engraftment of donor HSC in immunocompetent mice (Xue
et al, Blood 2010). However, since even low doses of irra-
diation have long-term risks, particularly in children, an
important goal is to develop improved regimens utilizing
c-Kit blockade.
Objective: To determine if replacing low dose irradiation
(LD-IR) with chemotherapy will synergize with c-Kit
blockade and improve engraftment in a congenic mouse
transplant model.
Methods: Mice were transplanted according to standard
protocol. C57B6 (CD45.2) mice were used as donors, and F1
progeny of C57B6 and BoyJ mice (CD45.1) were used as
recipients. Recipient mice were treated with 2 mg of the KIT-
blocking monoclonal antibody ACK2 (injected intraperito-
neally) combined with various schedules of Fludarabine
100mg/kg IP / Cyclophosphamide 200mg/kg IP (FluCy); or
5-ﬂurouracil (5-FU )150 mg/kg IP; or Busulfan (Bu) 20mg/kg
IP. Control mice were treated with the ACK2 and 300 cGy.
This was followed by transplantation of 1- 2 million freshly
isolated congenic marrow cells and subsequent long-term
engraftment analysis by ﬂow cytometry.
Results: In comparison to ACK2/LD-IR, the level of engraft-
ment post-transplant was much lower in all of the other
treatment arms. ACK2/FluCy had < 5% engraftment at 13
weeks compared to 80% engraftment in the ACK2/LD-IR arm.
ACK2/Bu had < 5% engraftment compared to 70% in the
ACK2/LD-IR arm at 20 weeks and ACK2/5-FU had < 5%
compared to 80% engraftment at 13 weeks in the ACK2/LDR
arm.
Conclusion: Our study demonstrates that combination of
antibody-mediated c-Kit blockade and chemotherapy did
not enhance congenic donor cell engraftment, at least in the
regimens tested. Further experiments to elucidate how LD-IR
and c-Kit blockade synergize to deplete HSCs and enhance
engraftment are ongoing.277
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